Scilex Holding (NASDAQ:SCLX - Get Free Report) insider Jaisim Shah bought 30,000 shares of the company's stock in a transaction dated Wednesday, October 16th. The shares were acquired at an average cost of $0.99 per share, with a total value of $29,700.00. Following the acquisition, the insider now directly owns 77,333 shares of the company's stock, valued at approximately $76,559.67. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Scilex Stock Performance
NASDAQ:SCLX opened at $0.95 on Friday. Scilex Holding has a one year low of $0.73 and a one year high of $2.63. The stock has a market cap of $181.55 million, a PE ratio of -0.66 and a beta of 1.15. The stock has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.25.
Scilex (NASDAQ:SCLX - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The company had revenue of $16.37 million during the quarter, compared to analysts' expectations of $13.17 million. As a group, analysts predict that Scilex Holding will post -1.19 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction
From Paradigm Press | Ad
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs…
A predicted Trump would win.
You won’t believe what he’s predicting now.
Click here to see it because it’s a SHOCKER…
Separately, Alliance Global Partners initiated coverage on shares of Scilex in a research report on Wednesday. They set a "buy" rating and a $14.00 price target on the stock.
View Our Latest Analysis on SCLX
Institutional Investors Weigh In On Scilex
Several hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new position in Scilex in the 2nd quarter valued at about $25,000. Bank of New York Mellon Corp acquired a new position in Scilex in the second quarter valued at approximately $31,000. Collective Family Office LLC grew its position in Scilex by 68.4% in the first quarter. Collective Family Office LLC now owns 21,950 shares of the company's stock worth $35,000 after acquiring an additional 8,918 shares during the period. Cannon Global Investment Management LLC acquired a new stake in Scilex during the first quarter worth $40,000. Finally, XTX Topco Ltd lifted its stake in shares of Scilex by 321.4% in the 2nd quarter. XTX Topco Ltd now owns 105,431 shares of the company's stock valued at $203,000 after purchasing an additional 80,409 shares during the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.
Scilex Company Profile
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
